KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Invested Capital (2016 - 2025)

Historic Invested Capital for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $1.1 billion.

  • Supernus Pharmaceuticals' Invested Capital rose 68.05% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 68.05%. This contributed to the annual value of $1.1 billion for FY2024, which is 1124.57% up from last year.
  • Supernus Pharmaceuticals' Invested Capital amounted to $1.1 billion in Q3 2025, which was up 68.05% from $1.1 billion recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Invested Capital registered a high of $1.3 billion during Q3 2022, and its lowest value of $786.0 million during Q1 2021.
  • Over the past 5 years, Supernus Pharmaceuticals' median Invested Capital value was $990.5 million (recorded in 2023), while the average stood at $1.0 billion.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Invested Capital soared by 5405.62% in 2021, and later plummeted by 2428.6% in 2023.
  • Over the past 5 years, Supernus Pharmaceuticals' Invested Capital (Quarter) stood at $1.2 billion in 2021, then fell by 24.08% to $907.3 million in 2022, then increased by 7.3% to $973.6 million in 2023, then increased by 11.25% to $1.1 billion in 2024, then dropped by 2.05% to $1.1 billion in 2025.
  • Its Invested Capital was $1.1 billion in Q3 2025, compared to $1.1 billion in Q2 2025 and $1.1 billion in Q1 2025.